IASLC TTLC 2022 | Entrectinib in patients with solid tumors and brain metastases

Christian Rolfo, MD, PhD, MBA, The Tisch Cancer Institute at Mount Sinai, New York, NY, comments on the use of entrectinib, a selective tyrosine kinase inhibitor (TKI), in patients with solid tumors and brain metastases. In an integrated analysis, entrectinib was found to produce a durable duration of response (DoR) and overall survival (OS) in patients. Prof. Rolfo highlights the promising nature of entrectinib, as it represents a novel therapeutic option for patients with brain metastases. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).